These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 973959)

  • 21. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.
    Ishibashi T; Mitomi A; Tatebe S; Imai S
    Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man.
    De Plaen JF; Amery A; Reybrouck T
    Eur J Clin Pharmacol; 1976 Sep; 10(5):297-303. PubMed ID: 789082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experiments in animals on the pharmacological effects of metipranolol in comparison with propranolol and pindolol.
    Bartsch W; Sponer G; Dietmann K
    Arzneimittelforschung; 1977; 27(12):2319-22. PubMed ID: 23798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinicopharmacological studies with pindolol following intravenous and oral administration].
    Aellig WH
    Adv Clin Pharmacol; 1976; 11():9-13. PubMed ID: 1032575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.
    Conway FJ; Fitzgerald JD; McAinsh J; Rowlands DJ; Simpson WT
    Br J Clin Pharmacol; 1976 Apr; 3(2):267-72. PubMed ID: 973955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.
    Cambridge D; Whiting MV; Allan G
    Br J Pharmacol; 1988 Jan; 93(1):165-75. PubMed ID: 2894874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity and duration of action of pindolol and alprenolol compared in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Dec; 14(5):305-8. PubMed ID: 729623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity.
    Broeder CE; Thomas EL; Martin NB; Hofman Z; Jesek JK; Scruggs KD; Wambsgans KC; Wilmore JH
    Am J Cardiol; 1993 Nov; 72(15):1188-95. PubMed ID: 8237812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels and beta-adrenoceptor blockade with acebutolol, practolol and propranolol in man.
    Cuthbert MF; Collins RF
    Br J Clin Pharmacol; 1975 Feb; 2(1):49-55. PubMed ID: 1234486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Beta-blocking actions and the partial agonist activity of bopindolol, a new beta-adrenoceptor antagonist, and its two metabolites].
    Chin WP; Sun HT; Kawada T; Imai S
    Nihon Yakurigaku Zasshi; 1989 Jul; 94(1):27-33. PubMed ID: 2571551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of acebutolol and practolol on the lipolytic response to isoprenaline.
    Gibbons DO; Lant AF; Ashford A; Collins RF; Pinder S
    Br J Clin Pharmacol; 1976 Feb; 3(1):177-84. PubMed ID: 973938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs.
    Gugler R; Krist R; Raczinski H; Höffgen K; Bodem G
    Br J Clin Pharmacol; 1980 Oct; 10(4):337-43. PubMed ID: 6108780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral vascular effects of bufuralol in hypertensive and normal subjects: a comparison with propranolol and pindolol.
    Johnston GD; Finch MB; Shanks RG
    Eur J Clin Pharmacol; 1986; 30(6):649-52. PubMed ID: 3533562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.
    Salako LA; Falase AO; Ragon A; Adio RA
    Eur J Clin Pharmacol; 1979 Jun; 15(5):299-304. PubMed ID: 37094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol.
    Tomlinson B; Cronin CJ; Graham BR; Prichard BN
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S69-75. PubMed ID: 2454372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative beta-adrenoreceptor-blocking effects and pharmacokinetics or propranolol and pindolol in hypertensive Africans.
    Salako LA; Falase AO; Aderounmu AF
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():393s-396s. PubMed ID: 232026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of beta-adrenoceptor blockers with and without intrinsic sympathomimetic activity on heart rate, arrhythmias and ST-T segments, using ambulatory electrocardiography.
    Northcote RJ; Ballantyne D
    Br J Clin Pharmacol; 1988 Feb; 25(2):179-85. PubMed ID: 3358881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol.
    Harms HH; Gooren L; Spoelstra AJ; Hesse C; Verschoor L
    Br J Clin Pharmacol; 1978 Jan; 5(1):19-26. PubMed ID: 23133
    [No Abstract]   [Full Text] [Related]  

  • 40. Proceedings: Pharmacological studies with LL 21-945, a new beta-adrenoceptor blocking agent with a long duration of action.
    Clark BJ; Saameli K; Troxler F
    Br J Pharmacol; 1974 Sep; 52(1):123P. PubMed ID: 4155983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.